SG11202010821TA - Vaccine composition - Google Patents

Vaccine composition

Info

Publication number
SG11202010821TA
SG11202010821TA SG11202010821TA SG11202010821TA SG11202010821TA SG 11202010821T A SG11202010821T A SG 11202010821TA SG 11202010821T A SG11202010821T A SG 11202010821TA SG 11202010821T A SG11202010821T A SG 11202010821TA SG 11202010821T A SG11202010821T A SG 11202010821TA
Authority
SG
Singapore
Prior art keywords
vaccine composition
vaccine
composition
Prior art date
Application number
SG11202010821TA
Other languages
English (en)
Inventor
Sumi Biswas
Jing Jin
Rebecca Alice Dabbs
Genevieve Marie Catherine Labbé
Original Assignee
Spybiotech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1807378.3A external-priority patent/GB201807378D0/en
Priority claimed from GBGB1807376.7A external-priority patent/GB201807376D0/en
Application filed by Spybiotech Ltd filed Critical Spybiotech Ltd
Publication of SG11202010821TA publication Critical patent/SG11202010821TA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6075—Viral proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/735—Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16123—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18523—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
SG11202010821TA 2018-05-04 2019-05-03 Vaccine composition SG11202010821TA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1807378.3A GB201807378D0 (en) 2018-05-04 2018-05-04 Vaccine composition
GBGB1807376.7A GB201807376D0 (en) 2018-05-04 2018-05-04 HMCV Vaccine Composition
PCT/GB2019/051245 WO2019211630A2 (en) 2018-05-04 2019-05-03 Vaccine composition

Publications (1)

Publication Number Publication Date
SG11202010821TA true SG11202010821TA (en) 2020-11-27

Family

ID=66484095

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202010821TA SG11202010821TA (en) 2018-05-04 2019-05-03 Vaccine composition

Country Status (11)

Country Link
US (1) US20210128717A1 (enrdf_load_stackoverflow)
EP (1) EP3787676A2 (enrdf_load_stackoverflow)
JP (2) JP7575096B2 (enrdf_load_stackoverflow)
KR (1) KR20210013571A (enrdf_load_stackoverflow)
CN (2) CN112638411B (enrdf_load_stackoverflow)
AU (1) AU2019263706A1 (enrdf_load_stackoverflow)
BR (1) BR112020022393A2 (enrdf_load_stackoverflow)
CA (1) CA3099381A1 (enrdf_load_stackoverflow)
IL (1) IL278418B2 (enrdf_load_stackoverflow)
SG (1) SG11202010821TA (enrdf_load_stackoverflow)
WO (1) WO2019211630A2 (enrdf_load_stackoverflow)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201917265D0 (en) * 2019-11-27 2020-01-08 Univ Sheffield Bonded neurotoxins
KR20220141787A (ko) * 2019-12-11 2022-10-20 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 볼거리 및 홍역 바이러스 면역원 및 이의 용도
CN114634578B (zh) * 2020-12-15 2024-04-02 榕森生物科技(北京)有限公司 针对新型冠状病毒感染的疫苗组合物
WO2022129547A1 (en) * 2020-12-18 2022-06-23 University Of Copenhagen Nucleic acid vaccines
WO2022234276A1 (en) * 2021-05-04 2022-11-10 SpyBiotech Limited Adenoviral vectors and vaccines thereof
CN114736272B (zh) * 2022-02-21 2022-09-06 悦康药业集团股份有限公司 一种优化病毒膜融合抑制剂的方法及广谱抗冠状病毒脂肽和应用
CN115920026B (zh) * 2022-04-02 2023-11-14 中山大学 耐热性多聚体蛋白支架、耐热性多聚体蛋白支架在疫苗中的应用
CN115010812B (zh) * 2022-04-12 2024-06-21 河南省龙星生物科技有限公司 一种非洲猪瘟抗原介导细胞免疫的多聚体及应用
CN116041536A (zh) * 2022-09-15 2023-05-02 山西大学 一种多接头自组装蛋白纳米颗粒的制备方法与应用
CN116983403B (zh) * 2022-09-30 2023-12-19 烟台派诺生物技术有限公司 一种预防或治疗水痘-带状疱疹病毒相关疾病的免疫组合物产品及其制备方法
CN117050149A (zh) * 2023-05-19 2023-11-14 珠海丽凡达生物技术有限公司 包含人呼吸道合胞病毒抗原的免疫组合物及其制备方法和应用
CN117264081B (zh) * 2023-11-21 2025-03-21 华南理工大学 一种双肽受体激动剂及其制备方法与应用
CN118373888B (zh) * 2024-06-27 2024-08-30 普大生物科技(泰州)有限公司 一种水痘-带状疱疹病毒纳米颗粒蛋白及其制备方法和应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7951384B2 (en) * 2005-08-05 2011-05-31 University Of Massachusetts Virus-like particles as vaccines for paramyxovirus
AU2008340949A1 (en) 2007-12-24 2009-07-02 Glaxosmithkline Biologicals S.A. Recombinant RSV antigens
WO2011009877A1 (de) 2009-07-24 2011-01-27 Basf Se Flammgeschützte polyamidformmassen
GB201002362D0 (en) 2010-02-11 2010-03-31 Isis Innovation Peptide tag systems that spontaneously form an irreversible link to protein partners via isopeptide bonds
CN104271745A (zh) * 2011-11-11 2015-01-07 变异生物技术公司 用于治疗巨细胞病毒的组合物和方法
JP2015522581A (ja) 2012-07-06 2015-08-06 ノバルティス アーゲー サイトメガロウイルスタンパク質の複合体
CA2902877A1 (en) 2013-03-13 2014-10-02 Jeffrey Boyington Prefusion rsv f proteins and their use
NZ721908A (en) * 2013-12-20 2022-12-23 Massachusetts Gen Hospital Combination therapy with neoantigen vaccine
EP3015475A1 (en) 2014-10-31 2016-05-04 Novartis AG Mammalian cells expressing cytomegalovirus antigens
EA035378B1 (ru) * 2015-01-15 2020-06-04 Юниверсити Оф Копенгаген Вирусоподобная частица с эффективным экспонированием эпитопов
GB201509782D0 (en) 2015-06-05 2015-07-22 Isis Innovation Methods and products for fusion protein synthesis
US11174292B2 (en) * 2016-03-29 2021-11-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Substitutions-modified prefusion RSV F proteins and their use
CN106081304A (zh) 2016-07-27 2016-11-09 佛山市高明金荣华乐金属制品有限公司 一种新型可折叠箱体及其拆装方法
GB201705750D0 (en) 2017-04-10 2017-05-24 Univ Oxford Innovation Ltd Peptide ligase and use therof
GB201706430D0 (en) 2017-04-24 2017-06-07 Univ Oxford Innovation Ltd Proteins and peptide tags with enhanced rate of spontaneous isopeptide bond formation and uses thereof

Also Published As

Publication number Publication date
US20210128717A1 (en) 2021-05-06
CA3099381A1 (en) 2019-11-07
IL278418B2 (en) 2024-01-01
CN112638411B (zh) 2025-03-04
BR112020022393A2 (pt) 2021-02-02
CN120040601A (zh) 2025-05-27
JP7575096B2 (ja) 2024-10-29
WO2019211630A2 (en) 2019-11-07
KR20210013571A (ko) 2021-02-04
IL278418A (enrdf_load_stackoverflow) 2020-12-31
CN112638411A (zh) 2021-04-09
JP2021523937A (ja) 2021-09-09
IL278418B1 (en) 2023-09-01
WO2019211630A3 (en) 2019-12-05
AU2019263706A1 (en) 2020-11-19
JP2024156964A (ja) 2024-11-06
EP3787676A2 (en) 2021-03-10

Similar Documents

Publication Publication Date Title
SG11202010821TA (en) Vaccine composition
GB201711635D0 (en) Immunogenic composition
GB201810492D0 (en) Composition
SG11202009147UA (en) Vaccine compositions
GB201802339D0 (en) Immunogenic composition
GB201811100D0 (en) Composition
GB201812145D0 (en) Composition
GB201711637D0 (en) Immunogenic composition
GB201804434D0 (en) Composition
GB2562241B (en) Vaccine compositions
SG11202103389WA (en) Immunogenic compositions
GB201910794D0 (en) Vaccine
GB201818827D0 (en) Composition
GB201801596D0 (en) Composition
EP3764991A4 (en) VACCINE COMPOSITION
GB201815031D0 (en) Composition
GB201703529D0 (en) Vaccine composition
GB201911636D0 (en) Vaccine
GB201811382D0 (en) Vaccine
GB201803692D0 (en) Immunogenic composition
GB201819861D0 (en) Composition
EP3677276A4 (en) VACCINE COMPOSITION
GB201815032D0 (en) Composition
GB201718251D0 (en) Vaccine Compositions
GB201810024D0 (en) Composition